Who Can Participate?
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Locations
Duke University Hospital
Duke Raleigh Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
EA3231, A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em (NCT06475989)
Principal Investigator
Jameel
Muzaffar
Protocol Number
PRO00117489
NCT ID
NCT06475989
Phase
III
Enrollment Status
Open to Enrollment